Oppenheimer analyst Jay Olson assumed coverage of Praxis Precision (PRAX) with an Outperform rating and $97 price target following quarterly results. Given the multiple upcoming readouts across its pipeline, the firm remains encouraged by management’s execution. For the vomatrigine program, Oppenheimer looks forward to the RADIANT and POWER1 registrational Phase 2/3 topline results, still expected in mid-2025 and the second half of 2025, respectively.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- AMD upgraded, Electronic Arts downgraded: Wall Street’s top analyst calls
- Praxis Precision initiated with a Buy at Chardan
- Praxis Precision Medicines: Advancements and Financial Outlook
- Praxis Precision price target raised to $76 from $73 at Baird
- Praxis Precision hosted investor event on clinical programs